Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
|Poll|October 12, 2011
A 7-Year-Old Girl With Hereditary Multiple Exostosis Presents With a Painful Mass on Her Right Femur
Author(s)Robert D. Cardiff, MD, PhD
Advertisement
A 7-year-old girl with hereditary multiple exostosis presents with a growing painful mass on her right femur. The following is an H&E stained slide of the mass.
The diagnosis is most likely:
Advertisement
Related to this article
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
5